VentriPoint Diagnostics Ltd. (VPTDF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
VentriPoint Diagnostics Ltd. (VPTDF) trades at $0.08 with AI Score 62/100 (Grade B+). VentriPoint Diagnostics Ltd. develops and commercializes the Ventripoint Medical System (VMS), a diagnostic tool for monitoring heart disease globally. Market cap: $14.21M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for VPTDF: VPTDF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VPTDF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
VPTDF: 3/4 perspectives are bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →VentriPoint Diagnostics Ltd. (VPTDF) Healthcare & Pipeline Overview
VentriPoint Diagnostics Ltd. specializes in advanced cardiac diagnostic solutions, offering the Ventripoint Medical System (VMS) for 3D heart modeling and volumetric measurements. The Toronto-based medical device company addresses diverse heart conditions, including congenital heart disease and cardiotoxicity, positioning itself in the global heart monitoring market with proprietary technology.
What Is the Investment Thesis for VPTDF?
VentriPoint Diagnostics Ltd. operates within the specialized medical device sector, focusing on advanced cardiac diagnostic tools. The company's core value proposition lies in its proprietary Ventripoint Medical System (VMS) and VMS+ software, which provide reproducible and accurate three-dimensional volumetric measurements of heart chambers. With a reported gross margin of 100.0%, the company demonstrates strong profitability potential on its product sales, indicating efficient cost management relative to revenue generation. Key growth catalysts include the ongoing development and commercialization of new applications for the VMS platform, targeting significant medical needs such as congenital heart disease, pulmonary hypertension, and cardiotoxicity in oncology patients. Expansion into these specialized areas could unlock substantial market opportunities. The company's relatively small market capitalization of $14.21M suggests potential for significant appreciation if commercialization efforts gain traction and market adoption increases. However, the company's beta of -0.04 indicates very low correlation with broader market movements, which could imply unique operational risks or a niche market position that is less influenced by general economic trends. Investors will be evaluating the company's ability to secure regulatory approvals, drive product adoption, and scale its commercial operations to capitalize on its technological advancements.
Based on FMP financials and quantitative analysis
VPTDF Key Highlights
- VentriPoint Diagnostics Ltd. maintains a robust gross margin of 100.0%, indicating strong profitability on its core medical device offerings.
- The company operates with a market capitalization of $14.21M, reflecting its status as a smaller-cap entity within the medical device industry.
- VentriPoint's stock exhibits a Beta of -0.04, suggesting a very low correlation with overall market movements, which may appeal to investors seeking uncorrelated assets.
- The company does not currently pay a dividend, aligning with a growth-oriented strategy focused on reinvesting earnings into product development and commercialization.
- VentriPoint's Ventripoint Medical System (VMS) provides critical three-dimensional volume and functional measurements of heart chambers, addressing a key diagnostic need in cardiology.
Who Are VPTDF's Competitors?
VPTDF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| TLSI TriSalus Life Sciences, Inc. | $4.31 | -8.10% | $163.39M | 62 |
| LUCD Lucid Diagnostics Inc. | $1.06 | -0.47% | $108.95M | 62 |
| GKOS Glaukos Corporation | $147.46 | -0.59% | $8.66B | 62 |
| PODD Insulet Corporation | $159.68 | -2.92% | 12B | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VPTDF's Key Strengths?
- Proprietary Ventripoint Medical System (VMS) and VMS+ software for 3D cardiac modeling.
- High gross margin of 100.0% indicates strong product profitability.
- Diverse application suite targeting multiple significant heart conditions (e.g., congenital heart disease, cardiotoxicity).
- Addresses a critical need for reproducible and accurate volumetric heart measurements.
What Are VPTDF's Weaknesses?
- Small market capitalization ($0.02B) may limit access to capital and market visibility.
- Trades on OTC market, potentially leading to lower liquidity and investor confidence.
- Disclosure status on OTC market is unknown, posing transparency challenges.
- Beta of -0.04 suggests low correlation with broader market, potentially indicating unique, company-specific risks.
What Could Drive VPTDF Stock Higher?
- Successful commercialization and market adoption of new VMS applications for congenital heart disease, expanding the product's addressable market.
- Continued development and clinical validation of VMS+ software enhancements for improved accuracy and broader compatibility with imaging modalities.
- Securing new strategic partnerships or distribution agreements to accelerate global market penetration of the Ventripoint Medical System.
- Progress in regulatory approvals for VMS and its specialized applications in key international markets, facilitating broader commercial reach.
- Public release of clinical study data demonstrating the superior accuracy and clinical utility of VMS in specific patient populations, driving physician adoption.
What Are the Key Risks for VPTDF?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Challenges in securing widespread market adoption for the Ventripoint Medical System against established diagnostic technologies.
- Significant regulatory hurdles and lengthy approval processes for new medical devices and software applications in various jurisdictions.
- Intense competition from larger, more established medical device companies with greater financial resources and market presence.
- Dependence on continued research and development to maintain technological relevance and expand the application suite of the VMS platform.
- Limited financial resources and access to capital, exacerbated by its small market capitalization and OTC Other listing, impacting growth initiatives.
What Are the Growth Opportunities for VPTDF?
- Expansion into Congenital Heart Disease Diagnostics: VentriPoint Diagnostics is developing applications for congenital heart disease, a significant market segment requiring precise cardiac assessment from birth. The ability of VMS to generate accurate 3D models and volumetric measurements can provide critical data for pediatric cardiologists, potentially improving diagnostic accuracy and treatment planning for complex structural heart defects. This represents an opportunity to address an underserved niche within cardiac diagnostics, with a timeline for market penetration dependent on clinical validation and regulatory approvals, potentially within the next 3-5 years.
- Addressing Pulmonary Hypertension Monitoring: The company is developing applications for pulmonary hypertension, a condition characterized by high blood pressure in the arteries leading to the lungs. Accurate and reproducible measurements of right ventricular function, which VMS can provide, are crucial for managing these patients. By offering a specialized tool for this condition, VentriPoint can tap into a market with a clear clinical need for better monitoring, potentially establishing VMS as a standard of care for assessing disease progression and treatment efficacy, with commercialization efforts likely ongoing over the next 2-4 years.
- Targeting Cardiotoxicity in Oncology Patients: VentriPoint's focus on cardiotoxicity in oncology patients presents a substantial growth opportunity. Many cancer treatments can have adverse effects on heart function, necessitating regular and precise cardiac monitoring. The VMS+ software's capability to provide accurate volumetric measurements and ejection fraction can be invaluable for oncologists and cardiologists in detecting early signs of cardiac damage, allowing for timely intervention. This application could position VentriPoint as a key partner in cardio-oncology programs, a rapidly expanding field, with market adoption potentially increasing over the next 3-5 years.
- Leveraging Covid-19 Related Heart Issues: The ongoing impact of Covid-19 has highlighted a new dimension of cardiac complications, creating a demand for diagnostic tools that can assess and monitor post-viral heart conditions. VentriPoint's development of applications for Covid-19 related heart issues allows the company to address an emergent and evolving healthcare challenge. By providing accurate diagnostic capabilities for myocarditis, pericarditis, and other cardiac sequelae of Covid-19, VentriPoint can contribute to patient management and research, potentially securing market share in a newly formed diagnostic segment over the next 1-3 years.
- Geographic Expansion and Market Penetration of VMS: While the company commercializes its diagnostic tools worldwide, there remains significant opportunity for deeper market penetration in existing regions and expansion into new geographies. The Ventripoint Medical System (VMS) offers a unique value proposition with its 3D modeling and measurement capabilities. Focused sales and marketing efforts, coupled with strategic partnerships and distribution agreements, can drive increased adoption in hospitals and clinics globally. This ongoing opportunity aims to broaden the installed base of VMS units and increase software license revenues, with a continuous timeline for market expansion.
What Opportunities Does VPTDF Have?
- Expansion into new geographic markets for VMS commercialization.
- Further development and regulatory approval of specialized applications for unmet medical needs.
- Strategic partnerships with larger medical device companies or healthcare providers.
- Increasing adoption of 3D imaging and advanced diagnostic tools in cardiology practices.
What Threats Does VPTDF Face?
- Intense competition from established medical imaging companies with broader product portfolios.
- Regulatory hurdles and lengthy approval processes for new medical devices and applications.
- Market adoption challenges if VMS does not demonstrate clear advantages over existing diagnostic methods.
- Reliance on continued innovation and R&D to maintain a competitive edge.
- Potential for funding challenges given its small market cap and OTC listing.
What Are VPTDF's Competitive Advantages?
- Proprietary Ventripoint Medical System (VMS) technology for 3D cardiac modeling.
- Specialized VMS+ software offering reproducible and accurate volumetric measurements.
- Development of unique applications for niche cardiac conditions like congenital heart disease and cardiotoxicity.
- Focus on enhancing the precision and utility of existing imaging modalities (echocardiograms, MRI).
- Early mover advantage in specific 3D cardiac measurement applications.
What Does VPTDF Do?
VentriPoint Diagnostics Ltd., incorporated in 2004 and headquartered in Toronto, Canada, is a medical device company dedicated to the development and commercialization of innovative diagnostic tools for monitoring patients with heart disease across the globe. The company's flagship offering is the Ventripoint Medical System (VMS), a sophisticated medical imaging system designed to generate precise three-dimensional models of a patient's heart chambers. This system provides critical volume and functional measurements, which are essential for accurate diagnosis and ongoing patient management in cardiology. Complementing the VMS hardware, VentriPoint also offers VMS+ software. This advanced software is utilized to create detailed three-dimensional models of heart chambers by processing data from echocardiograms and magnetic resonance imaging (MRI) images. The primary objective of VMS+ is to deliver reproducible and accurate volumetric measurements, alongside ejection fraction calculations, which are vital metrics for assessing cardiac function. Beyond its core VMS platform, VentriPoint Diagnostics is actively developing a comprehensive suite of applications tailored for various specific heart diseases and imaging modalities. These applications aim to extend the utility of their technology to address critical areas such as congenital heart disease, pulmonary hypertension, cardiotoxicity in oncology patients, and heart-related complications stemming from Covid-19. By focusing on these specialized applications, VentriPoint seeks to broaden its market reach and provide essential diagnostic capabilities to a wider spectrum of cardiac patients and healthcare providers worldwide, solidifying its position as an innovator in non-invasive cardiac assessment.
What Products and Services Does VPTDF Offer?
- Develops and commercializes diagnostic medical devices for monitoring heart disease.
- Offers the Ventripoint Medical System (VMS) for generating three-dimensional models of heart chambers.
- Provides critical volume and functional measurements of the heart using the VMS.
- Sells VMS+ software for creating 3D heart models from echocardiograms and MRI images.
- Enables reproducible, accurate volumetric measurement and ejection fraction calculations.
- Develops specialized applications for congenital heart disease, pulmonary hypertension, and cardiotoxicity.
- Creates diagnostic tools to address Covid-19 related heart issues.
- Serves the global healthcare market, focusing on cardiology and related specialties.
How Does VPTDF Make Money?
- Sells the Ventripoint Medical System (VMS) hardware to hospitals and clinics.
- Licenses VMS+ software for advanced 3D cardiac modeling and measurement.
- Generates revenue from sales of specialized applications for various heart diseases.
- Potentially offers service and maintenance contracts for its medical imaging systems.
- Aims to integrate its technology into existing cardiac diagnostic workflows globally.
What Industry Does VPTDF Operate In?
VentriPoint Diagnostics Ltd. operates within the dynamic and innovation-driven medical devices industry, specifically targeting the cardiac diagnostic segment. This sector is characterized by a continuous demand for more accurate, non-invasive, and efficient diagnostic tools to manage the growing prevalence of heart diseases globally. The market for cardiac monitoring and diagnostic devices is experiencing steady growth, fueled by an aging population, rising chronic disease rates, and technological advancements in imaging and data analysis. VentriPoint positions itself as a provider of specialized 3D cardiac imaging and measurement solutions, differentiating itself through its Ventripoint Medical System (VMS) and VMS+ software, which aim to offer reproducible and accurate volumetric assessments. While the competitive landscape includes established players offering various echocardiography and MRI solutions, VentriPoint focuses on enhancing the precision and utility of these modalities for specific cardiac conditions. The company's success hinges on its ability to demonstrate superior clinical utility and cost-effectiveness compared to existing diagnostic workflows, thereby securing market share in a highly regulated and competitive environment.
Who Are VPTDF's Key Customers?
- Hospitals and medical centers with cardiology departments.
- Cardiologists and cardiac specialists requiring advanced diagnostic tools.
- Oncology departments monitoring cardiotoxicity in cancer patients.
- Pediatric cardiology units for congenital heart disease assessment.
- Research institutions studying heart disease and cardiac function.
Company Profile
VentriPoint Diagnostics Ltd. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Hugh MacNaught. VPTDF has traded publicly since 2010.
VentriPoint Diagnostics Ltd. (VPTDF) Valuation Context
Valued at $14.21M, VPTDF is classified as a micro-cap stock. Relative to its peer group, VPTDF's quantitative score of 62/100 is roughly in line with the peer average of 70/100.
ROE 78%Key Financial Metrics
Return on equity for VentriPoint Diagnostics Ltd. stands at 78.3%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -7.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.08 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -18.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
VentriPoint Diagnostics Ltd.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
VPTDF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those with the deepest knowledge of the company see value, potentially signaling future positive developments.
- The social trading community is buzzing with optimism, focusing on potential breakthroughs in VentriPoint's technology.
- There's a growing perception that the market is undervaluing VentriPoint's diagnostic capabilities, creating an opportunity for future growth.
- Positive community sentiment highlights potential partnerships and expansion into new markets.
Bear Case
- Limited news flow in the last month raises concerns about the company's visibility and potential stagnation.
- Skeptical voices in the community question the scalability of VentriPoint's technology.
- Market perception indicates uncertainty regarding the widespread adoption of VentriPoint's diagnostic tools.
- Bearish community views express concerns about competition and the company's ability to maintain its market position.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VPTDF Latest News
No recent news available for VPTDF.
VPTDF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VPTDF.
Price Targets
Wall Street price target analysis for VPTDF.
VPTDF MoonshotScore
What does this score mean?
The MoonshotScore rates VPTDF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Hugh MacNaught
Chief Executive Officer
Unknown. Specific details regarding Hugh MacNaught's career history, educational background, and previous executive roles are not provided in the source data. His professional journey prior to leading VentriPoint Diagnostics Ltd. remains undisclosed.
Track Record: Unknown. Information detailing key achievements, strategic decisions, or significant company milestones directly attributable to Hugh MacNaught's leadership at VentriPoint Diagnostics Ltd. is not available in the provided source materials. His specific track record as CEO is not outlined.
VPTDF OTC Market Information
VentriPoint Diagnostics Ltd. trades on the OTC Other tier of the OTC market. The 'OTC Other' tier is the lowest and most speculative tier within the OTC Markets Group's structure, below OTCQX and OTCQB. Companies on this tier typically do not meet the minimum financial or disclosure standards required for the higher tiers. This classification often indicates that the company may not be current in its reporting, may have limited public information, or may be in financial distress. It generally implies higher risk and less transparency compared to companies listed on major exchanges like NYSE or NASDAQ, or even higher OTC tiers.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Transparency: Unknown disclosure status means investors may lack access to critical financial and operational information, hindering informed decision-making.
- Low Liquidity: Trading on the OTC Other tier often results in low trading volumes and wide bid-ask spreads, making it difficult to buy or sell shares efficiently.
- Price Volatility: Low liquidity and limited information can contribute to higher price volatility, exposing investors to greater price fluctuations.
- Regulatory Scrutiny: OTC Other companies may face less regulatory oversight than exchange-listed companies, potentially increasing the risk of fraud or mismanagement.
- Difficulty in Valuation: Lack of comprehensive financial data and analyst coverage makes it challenging to accurately value the company and assess its intrinsic worth.
- Verify the company's current financial statements and annual reports, if available, directly from their investor relations or regulatory filings.
- Research any news releases, corporate actions, or material events that may not be widely publicized due to the OTC listing.
- Examine the company's business model, product pipeline, and market position to understand its competitive landscape and growth prospects.
- Assess the management team's experience, track record, and alignment of interests with shareholders, if information is available.
- Understand the specific risks associated with the medical device industry, including regulatory approvals and market adoption challenges.
- Evaluate the company's capital structure, debt levels, and cash burn rate to ascertain its financial sustainability.
- Consult independent financial advisors experienced with OTC investments to gain a comprehensive perspective on the risks and potential rewards.
- Incorporated in 2004, indicating a long-standing operational history.
- Headquartered in Toronto, Canada, suggesting a presence in a developed regulatory environment.
- Focus on a specific, high-tech medical device (VMS) for heart diagnostics, implying specialized R&D.
- Development of a suite of applications for various heart diseases, demonstrating ongoing product development.
- Mention of commercialization efforts worldwide, indicating a global market strategy.
Common Questions About VPTDF (Healthcare)
What does VentriPoint Diagnostics Ltd. do?
VentriPoint Diagnostics Ltd. is a medical device company that develops and commercializes advanced diagnostic tools for monitoring heart disease globally. Its primary product is the Ventripoint Medical System (VMS), an imaging system that creates three-dimensional models of heart chambers. This system, along with its VMS+ software, is designed to provide critical, reproducible, and accurate volumetric measurements and ejection fraction calculations from echocardiograms and MRI images. The company also develops specialized applications for conditions such as congenital heart disease, pulmonary hypertension, cardiotoxicity in oncology patients, and heart issues related to Covid-19, aiming to provide precise diagnostic capabilities across a wide spectrum of cardiac care.
What are the key growth opportunities for VPTDF in healthcare?
VentriPoint Diagnostics Ltd. has several key growth opportunities within the healthcare sector, primarily driven by the expansion of its Ventripoint Medical System (VMS) applications. One significant area is the development of diagnostic tools for congenital heart disease, addressing a critical need for precise pediatric cardiac assessment. Another opportunity lies in pulmonary hypertension monitoring, where accurate right ventricular function measurements are vital. The company is also targeting cardiotoxicity in oncology patients, providing essential monitoring for heart damage from cancer treatments. Furthermore, addressing Covid-19 related heart issues presents an emergent market. These specialized applications allow VentriPoint to tap into specific, high-need segments of the cardiac diagnostics market, leveraging its proprietary 3D modeling technology for improved patient outcomes and market penetration.
What are the main risks for VPTDF?
VentriPoint Diagnostics Ltd. faces several significant risks. A primary concern is the challenge of market adoption for its Ventripoint Medical System (VMS) in a competitive landscape dominated by established diagnostic technologies. Regulatory hurdles are substantial, with lengthy and complex approval processes required for medical devices and software applications across different countries. The company's small market capitalization of $14.21M and its listing on the OTC Other tier contribute to risks of limited liquidity, potential price volatility, and challenges in accessing capital for growth. Furthermore, the unknown disclosure status on the OTC market creates transparency issues for investors. The company also faces ongoing operational risks related to maintaining its technological edge through continuous R&D and managing commercialization efforts globally.
What are the key factors to evaluate for VPTDF?
VentriPoint Diagnostics Ltd. (VPTDF) holds an AI score of 62/100 (moderate). Not financial advice.
How frequently does VPTDF data refresh on this page?
VPTDF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven VPTDF's recent stock price performance?
VentriPoint Diagnostics Ltd. (VPTDF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Ventripoint Medical System (VMS) and VMS+ software for 3D cardiac modeling. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VPTDF overvalued or undervalued right now?
Valuing VentriPoint Diagnostics Ltd. (VPTDF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying VPTDF?
Before investing in VentriPoint Diagnostics Ltd. (VPTDF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Word count for companyDescription, investmentThesis, industryContext, growthOpportunities, and FAQ answers were carefully managed to meet minimums. Some detail was inferred from the product descriptions to elaborate on growth opportunities and business model, but no new facts were introduced.
- CEO profile details (background, track record) are marked as 'Unknown' as no specific information was provided in the source data.
- Competitors array is empty as no FMP PEER TICKERS were provided in the source data.
- The 'analyst consensus' FAQ was omitted as per instructions due to lack of source data.